Mesalamine 4 gm/60 mL Rectal Enema
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 72
- Registration Number
- NCT00840203
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 48
- Registration Number
- NCT00840099
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 66
- Registration Number
- NCT00840411
- Locations
- 🇺🇸
Gateway Medical Research, Saint Charles, Missouri, United States
Cefprozil 500 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 38
- Registration Number
- NCT00840281
- Locations
- 🇺🇸
Gateway Medical Research, Saint Charles, Missouri, United States
Trandolapril 4 mg Tablet Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT00840632
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Meloxicam 15 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 28
- Registration Number
- NCT00840476
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT00840216
- Locations
- 🇺🇸
Gateway Medical Research Inc., Saint Charles, Missouri, United States
600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 48
- Registration Number
- NCT00840840
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Trandolapril 4 mg Tablet Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 50
- Registration Number
- NCT00840073
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Cilostazol 100 mg Tablet Formulations Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 36
- Registration Number
- NCT00838630
- Locations
- 🇺🇸
Gateway Medical Research Inc., Saint Charles, Missouri, United States